Bradley L. Campbell is the President and Chief Operating Officer of Amicus Therapeutics (NASDAQ: FOLD) and is also a member of the Board of Directors. He brings nearly 20 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and leads the global organization responsible for the commercialization of GalafoldTM. He also oversees the Technical Operations, Market Access and Program Management functions.
Prior to Amicus, Mr. Campbell spent time in various commercial and business development roles at Genzyme and Bristol-Myers Squibb and as a strategy consultant for Marakon Associates.
Mr. Campbell currently serves on a number of Boards including Progenics Pharmaceuticals (NASDAQ: PGNX), the Association for Regenerative Medicine (ARM), and the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. He received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.